<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0804210673
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pentaxim
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIPHTHERIA TOXOID,TETANUS TOXOID,PERTUSSIS TOXOID,FILAMENTOUS HAEMAGGLUTININ,INACTIVATED POLIOMYELITIS VIRUS TYPE 1 (MAHONEY STRAIN),INACTIVATED POLIOMYELITIS VIRUS TYPE 2 (MEF-1 STRAIN),INACTIVATED POLIOMYELITIS VIRUS TYPE 3 (SAUKETT STRAIN),HAEMOPHILUS INFLUENZAE TYPE B
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30,40,25,25,40,8,32,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        110.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI PASTEUR" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI PASTEUR
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 634]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANOFI PASTEUR
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07CA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: bacterial and viral vaccines, combined - ATC code: J07CA06. PENTAXIM is a vaccine. Vaccines are used to protect against infectious diseases.<br />When PENTAXIM is injected, the body&rsquo;s natural defenses develop a protection against those diseases.<br />PENTAXIM is indicated to help protect your child against diphtheria, tetanus, pertussis, poliomyelitis and against invasive infections due to the Haemophilus influenzae type b bacterium (such as meningitis, blood poisoning, etc.). PENTAXIM is indicated in children from the age of 2 months.<br />It does not protect against infections caused by other types of Haemophilus influenzae or against meningitis due to other micro-organisms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use PENTAXIM, powder and suspension for suspension for injection in prefilled syringe:</strong><br />&bull; if your child is allergic (hypersensitive)<br />o to any of the vaccine components (listed in section 6 &ndash; Contents of the pack and other information),<br />o to glutaraldehyde, neomycin, streptomycin, or polymyxin B (used during the manufacturing process and which may be present as traces),<br />o to a pertussis vaccine (acellular or &ldquo;whole cell&rdquo;),<br />&bull; if your child had an allergic reaction after a previous injection of the same vaccine or a vaccine containing the same substances,</p><p>&bull; if your child suffers from evolving encephalopathy (cerebral lesions)<br />&bull; if your child suffered from encephalopathy (cerebral lesions) within 7 days of a previous dose of a pertussis vaccine (acellular or &quot;whole cells&quot; pertussis),<br />&bull; if your child has fever or a disease which occurred suddenly (acute disease), in this case it is preferable to postpone the vaccination.</p><p><strong>Warning and precautions</strong><br />Talk to your doctor or your pharmacist before using PENTAXIM.<br />&bull; if your child has blood disorders such as a decrease in platelets (thrombocytopenia) or clotting disorders because of the risk of bleeding which may occur during intramuscular administration,<br />&bull; if your child already presented with febrile convulsions, not related to a previous vaccine injection; in this case it is particularly important that temperature be monitored in the 48 hours following vaccination and that antipyretic treatment be regularly administered to help reduce fever, for 48 hours,<br />&bull; if your child experienced any of the following events after a previous administration of a vaccine (then the decision to give further doses of this pertussis-containing vaccine will be carefully evaluated):<br />o Fever of 40&deg;C or above within 48 hours of vaccination, not due to another identifiable cause.<br />o Collapse or shock-like state with hypotonic-hyporesponsive episode (drop in energy) within 48 hours of vaccination.<br />o Persistent, inconsolable crying lasting 3 hours or more, occurring within 48 hours of vaccination.<br />o Convulsions with or without fever, occurring within 3 days of vaccination.<br />&bull; if your child has or had medical issues or allergies, especially an allergic reaction following an injection of PENTAXIM,<br />&bull; if your child presented Guillain-Barr&eacute; syndrome (abnormal sensitivity, paralysis) or brachial neuritis (paralysis, diffuse pain in the arm and shoulder) following receipt of a prior vaccine containing tetanus toxoid (vaccine against tetanus), the decision to give any further vaccine containing tetanus toxoid should be evaluated by your doctor,<br />&bull; if your child presented swelling (oedematous reactions) in lower limbs following injection of a Haemophilus influenzae type b-containing vaccine; the diphtheria-tetanus-pertussis-poliomyelitis vaccine and the Haemophilus influenzae type b conjugate vaccine should then be administered into two separate injection sites and on different days,<br />&bull; if your child has poor immune defenses, or if he/she is treated with corticosteroids, cytotoxic drugs, radiotherapy or other drugs that may weaken his/her immune system: the immune response may be diminished. It is then recommended to wait until the end of the treatment or disease before vaccinating. However, vaccination is recommended in subjects with chronic immunodeficiency such as HIV infection, even if the immune response may be limited.<br />&bull; PENTAXIM does not protect against invasive diseases caused by serotypes other than<br />Haemophilus influenzae type b, or against meningitis of other origins.</p><p><strong>Children</strong><br />Not applicable.<br /><strong>Other medicines and PENTAXIM, powder and suspension for suspension for injection in prefilled syringe</strong><br />This vaccine can be administered simultaneously with the M-M-RVAXPRO vaccine or the HBVAXPRO vaccine, but in two separate sites, i.e. in two different parts of the body, such as the other arm or the other leg.<br />In case your child should receive PENTAXIM simultaneously with other vaccines than those already mentioned, please ask your doctor or pharmacist for more information.<br />Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines.</p><p><strong>PENTAXIM, powder and suspension for suspension for injection in prefilled syringe with food and drink</strong><br />Not applicable.<br /><strong>Pregnancy and breast-feeding</strong><br />Not applicable.<br /><strong>Driving and using machines</strong><br />Not applicable.<br /><strong>PENTAXIM, powder and suspension for suspension for injection in prefilled syringe contains</strong><br />Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This vaccine will be administered to your child by a healthcare professional.<br /><u><strong>Dosage</strong></u><br />The usual recommended schedule includes primary vaccination, consisting of three injections at an interval of one month from the age of 2 months, followed by one booster injection within the second year of life.<br /><u><strong>Method of administration</strong></u><br />Administration should be performed into a muscle, preferably in the anterolateral side of the thigh (middle third) in infants, and in the upper arm in children.<br /><strong>If you use more PENTAXIM, powder and suspension for suspension for injection in prefilled syringe than you should</strong><br />Not applicable.<br /><strong>If you forget to use PENTAXIM, powder and suspension for suspension for injection in prefilled syringe</strong><br />If you forgot to have your child given a dose of vaccine, tell you doctor who will decide when to administer the dose.<br /><strong>If you stop using PENTAXIM, powder and suspension for suspension for injection in prefilled syringe</strong><br />Not applicable.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Serious allergic reactions</strong><br />Serious allergic reactions, although very rare, may occur following vaccination, generally while the child is still present on the place where he/she was vaccinated.<br /><strong>If any of the symptoms listed below occurs after you have left the place where your child was vaccinated, you must contact IMMEDIATELY a doctor or the emergency services.</strong><br />&bull; Swelling of the face (face oedema), sudden swelling of the face and neck (angioedema, Quincke&rsquo;s oedema).<br />&bull; Sudden and serious malaise with drop in blood pressure causing dizziness and loss of consciousness, accelerated heart rate associated with respiratory disorders (anaphylactic reaction and shock).</p><p><strong>Other side effects</strong><br />If your child experiences any of the following side effects listed below and it persists or gets serious, please contact your doctor or pharmacist.<br /><u>Very common reactions (may affect more than one in 10 children)</u><br />&bull; Loss of appetite.<br />&bull; Nervousness, irritability.<br />&bull; Abnormal crying.<br />&bull; Somnolence.<br />&bull; Vomiting.<br />&bull; Injection-site redness (erythema).<br />&bull; Fever 38&deg;C or higher.<br />&bull; Injection-site swelling (oedema).<br />&bull; Injection-site pain.<br /><u>Common reactions (may affect less than one in 10 children but more than one in 100 children)</u><br />&bull; Diarrhoea.<br />&bull; Injection-site hardening (induration).<br />&bull; Insomnia, sleep disorder.<br /><u>Uncommon reactions (may affect less than one in 100 children but more than one in 1000 children)</u><br />&bull; Injection site redness and swelling (oedema) of 5 cm or more.<br />&bull; Fever 39&deg;C or higher.<br />&bull; Inconsolable and prolonged crying (for more than 3 hours)<br /><u>Rare reactions (may affect less than one in 1000 children but more than one in 10 000 children)</u><br />&bull; Fever over 40&deg;C.<br />&bull; Swelling in legs and feet (oedematous reactions affecting lower limbs) with a bluish discoloration of the skin (cyanosis) or redness, small transient red spots (purpura) occurring within hours of vaccination, and disappearing without treatment and without sequelae. Swelling may be accompanied with severe crying.<br /><u>Reactions with a Not Known frequency (frequencies cannot be estimated because these reactions are reported very rarely)</u><br />&bull; Convulsions with or without fever.<br />&bull; Drops in energy or periods during which your child is pale, unresponsive or seems in a shock-like state (hypotony-hyporesponsiveness)<br />&bull; Skin rash, redness (erythema), itching (urticaria).<br />&bull; Large injection-site reactions, larger than 5 cm, including limb swelling (oedema) that may spread to the joints on both sides of the injection site. These reactions start within 24-72 hours after vaccination and may be associated with symptoms such as redness (erythema), warmth, tenderness or pain at the injection site. They resolve spontaneously within 3-5 days.<br />Potential side effects (i.e. that have not been reported directly with PENTAXIM, but with other vaccines containing one or more of the antigenic constituents of PENTAXIM) are the following:<br />&bull; Guillain-Barr&eacute; syndrome (abnormal sensitivity, paralysis) and brachial neuritis (paralysis, diffuse pain in the arm and shoulder) following the administration of a vaccine containing tetanus toxoid.<br /><u><strong>Additional information concerning specific populations</strong></u><br />In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination<br /><strong>Reporting of side effects</strong><br />If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system.<br />By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label, the box after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.<br />Do not use this medicine if you notice an abnormal colour or the presence of foreign particles.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What PENTAXIM, powder and suspension for suspension for injection in prefilled syringe contains</strong><br />&bull; The active substances are:<br />After reconstitution one dose (0.5 ml) contains:<br />Diphtheria toxoid (1) .......................................................................................................................................................................................... &ge; 30 IU<br />Tetanus toxoid (1) ............................................................................................................................................................................................... &ge; 40 IU<br />Bordetella pertussis antigens:<br />Pertussis toxoid (1) ......................................................................................................................................................................... 25 micrograms<br />Filamentous haemagglutinin (1) ........................................................................................................................................... 25 micrograms<br />Poliomyelitis virus (inactivated)<br />- type 1 (Mahoney strain) ...................................................................................................... 40 DU (2) (3) (4)<br />- type 2 (MEF-1 strain) ............................................................................................................ 8 DU (2) (3) (4)<br />- type 3 (Saukett strain) ......................................................................................................... 32 DU (2) (3) (4)<br />Polysaccharide of Haemophilus influenzae type b ............................................................. 10 micrograms<br />conjugated to the tetanus protein ................................................................................. 18-30 micrograms<br />(1) adsorbed on aluminium hydroxide, hydrated ........................................................................ 0.3 mg Al3+<br />(2) DU: D antigen unit.<br />(3) or equivalent antigenic quantity determined by a suitable immunochemical method.<br />(4) produced on VERO cells.<br />&bull; The other components are:<br />Suspension for injection:<br />o Hanks medium without phenol red<br />o Acetic acid glacial and/or sodium hydroxide (for pH adjustment)<br />o Formaldehyde<br />o Phenoxyethanol<br />o Ethanol<br />o Water for injections.<br />Hanks medium is a complex mixture of amino acids (including phenylalanine), mineral salts, vitamins and other components (such as glucose) diluted in water for injections.<br />Powder:<br />o Saccharose<br />o Tromethamol<br />o Concentrated hydrochloric acid for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PENTAXIM is a powder and a suspension for injection (0.5 ml in prefilled syringe with or without needle. Box of 1, 10 or 20.)
The powder is white and the solvent is cloudy and whitish. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong><br />SANOFI PASTEUR<br />14 ESPACE HENRY VALLEE<br />69007 LYON FRANCE<br /><strong>Secondary packaging:</strong><br />Arab Company for Pharmaceutical Products (ARABIO)<br />Plot # 6, Makkah Industrial Zone, Al Umrah District,<br />Makkah, Kingdome of Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة العلاجیة الدوائیة: اللقاحات البكتیر􀈄ة والفیروسیة، مجتمعة &ndash; رمز J07CA06 :ATC<br />بِنتاكسیم هو لقاح. تستخدم اللقاحات للحما 􀇽ة من الأم ا رض المعد 􀇽ة.</p><p>تبدأ دفاعات الجسم الطبیعیة ب تطو 􀈄ر حما 􀇽ة ضد تلك الأم ا ر ض 􀇼عد حقن بِنتاكسیم .<br />یوصى 􀇼استخدام بِنتاكسیم للمساعدة في حما 􀇽ة طفلك م ن الإصا 􀇼ة 􀇼عدوى الخناق والك ا زز والسعال الد 􀇽كي وشلل<br />الأطفال وضد الالتها 􀇼ات الغَزوَّ􀈄ة التي تسببها 􀇼كتیر􀈄ا المستدمیة النزلیة من النوع ب (مثل التهاب السحا 􀇽ا وتسمم<br />الدم، وما إلى ذلك). بِنتاكسیم مُعد للاستخدام لدى الأطفال بدءًا من عمر شهر􀈄ن .<br />لا 􀇽حمي بِنتاكسیم من الالتها 􀇼ات التي تسببها أنواع أخرى من المستدمیة النزلیة أو ضد التهاب السحا 􀇽ا الذي<br />تسببه الكائنات الحیة الدقیقة الأخرى .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم بِنتاكسیم؛ مس حوق ومُعلّق لتحضیر مُعلق للحقن في مِحقنة مسبقة التعبئة في الحالات التالیة:</strong><br />&bull; إذا 􀘗ان طفلك 􀇽عاني من حساسیة (فرط الحساسیة)<br />- نحو أيّ من مكونات اللقاح (المدرجة في الفقرة ٦ - محتو 􀈄ات العبوة ومعلومات أخرى)،<br />- نحو غلوتا ا رلدیهید أو نیوما 􀇽سین أو ستر􀈄بتوما 􀇽سین (مواد تُستخدم أثناء عملیة التصنیع والتي قد تكون<br />موجودة 􀇼كمیات ضئیلة في اللقاح)،<br />- نحو لقاح السعال الد 􀇽كي (اللاخلوي أو &quot;ذي الخلیة الكاملة&quot;)،<br />&bull; إذا تعرّض طفلك لرد فعل تحسسي 􀇼عد الحقن السابق لنفس اللقاح أو لقاح 􀇽 حتوي على نفس الموا د،<br />&bull; إذا 􀘗ان طفلك 􀇽عاني من اعتلال الدماغ المتطور تدر􀈄جیّا (الآفات الدماغیة )<br />&bull; إذا عانى طفلك من اعتلال دماغي (آفات دماغیة) في غضون ٧ أ 􀇽ام من تلقیه جرعة سا 􀇼قة من لقاح السعال<br />الد 􀇽كي (الخلوي أو اللاخلوي ).</p><p>&bull; إذا 􀘗ان طفلك 􀇽عاني من الحمى أو مرض مفاجىء (مرض حاد)، في هذه الحالة 􀇽فضل تأجیل التطعیم .<br /><strong>تح ذریا ت واحتیاطا ت</strong><br />تحدث إلى طبیبك أو الصیدلي قبل استخدام بِنتاكسیم إذا:<br />&bull; 􀘗ان طفلك 􀇽عاني من اضط ا ر 􀇼ات في الدم مثل انخفاض الصفائح الدمو 􀈄ة (نقص الصفیحات) أو اضط ا ر 􀇼ات<br />التخثر 􀇼سبب خطر التعرض للنز􀈄ف الذي قد 􀇽حدث أثناء الحقن العضلي ،<br />&bull; إذا 􀘗ان طفلك 􀇽عاني حالای من تشنجات حمو ّ􀈄ة، لا تتعلق 􀇼حقنة لقاح سا 􀇼قة؛ في هذه الحالة، من المهم 􀇼شكل<br />خاص م ا رقبة درجة الح ا ررة خلال ٤٨ ساعة التالیة للتطعیم وأن یتم إعطاؤه علاج خافض للح ا ررة 􀇼انتظام<br />للمساعدة في خفض الحمى لمدة ٤٨ ساعة ،<br />&bull; إذا تعرّض طفلك لأيّ من الأحداث التالیة 􀇼عد تلقي أيّ لقاح ( 􀇽جب حینها الت ا زم الحیطة في ق ا رر إعطائه أي<br />جرعات إضافیة من أيّ لقاح 􀇽حتوي على السعال الد 􀇽كي):<br />- حمّ ى تصل إلى ٤٠ درجة مئو 􀈄ة أو أعلى في غضون ٤٨ ساعة من تلقّي اللّقاح دون وجود سبب آخر<br />واضح لحدوثها.<br />- الانهیار الصحي أو حالة شبیهة 􀇼الصدمة مع نو 􀈃ات ارتخاء وانخفاض رد الفعل (تدنّي الطاقة) خلال<br />٤٨ ساعة من التطعیم .<br />- البكاء المُستمر بدون انقطاع لمدة ٣ ساعات أو أكثر مع صعو 􀈃ة تهدئته، خلال ٤٨ ساعة من التطعیم .<br />- التشنجات مع أو بدون حمى، التي تحدث في غضون ٣ أ 􀇽ام من التطعیم .<br />&bull; إذا 􀘗ان طفلك 􀇽عاني أو واجه في السابق مشاكل طبیة أو حساسیة، وخاصة رد فعل تحسسي 􀇼عد حقن<br />بِنتاكسیم،</p><p>&bull; إذا تعرض طفلك لمتلازمة غیلا ن- 􀇼ار􀈄ه (حساسیة غیر طبیعیة، شلل) أو التهاب عصب عضدي (شلل،<br />ألم منتشر في الذ ا رع والكتف) 􀇼عد تلقي لقاح سابق 􀇽حتوي على ذوفان الك ا زز (لقاح ضد الك ا زز)، فذلك<br />یتطلّب م ا رجعة ق ا رر إعطاء المز􀈄د من اللقاحات التي تحتوي على الك ا زز من قبل الطبیب .<br />&bull; ذإ ا تعرّض طفلك لتورم (وذمة) في الأط ا رف السفلیة 􀇼عد حقن لقاح 􀇽حتوي على المستدمیة النزلیة من النوع<br />ب؛ 􀇽جب إعطاء لقاح التهاب الخناق والك ا زز والسعال الد 􀇽كي وشلل الأطفال ولقاح المستدمیة النزلیة<br />المقترن من النوع ب في موقعین منفصلین للحقن وفي أ 􀇽ام مختلفة ،<br />&bull; إذا 􀘗ان طفلك 􀇽عاني من ضعف الدفاعات المناعیة، أو إذا 􀘗ان 􀇽عالج 􀇼الكورتیكوستیرو 􀈄دات أو الأدو 􀈄ة<br />السامة للخلا 􀇽ا أو العلاج الإشعاعي أو الأدو 􀈄ة الأخرى التي قد تضعف جهازه المناعي: فقد تقل<br />الاستجا 􀇼ة المناعیة للقاح لد 􀇽ه. یوصى في هذه الحالة 􀇼الانتظار حتى نها 􀇽ة العلاج أو المرض قبل<br />التطعیم. ومع ذلك، یوصى بتطعیم الأشخاص الذین 􀇽عانون من نقص المناعة المزمن مثل عدوى فیروس<br />نقص المناعة البشر􀈄ة، حتى لو 􀘗انت الاستجا 􀇼ة المناعیة لدیهم محدودة.<br />&bull; بِنتاكسیم لا 􀇽حمي من الأم ا رض الغ وز 􀈄ة التي تسببها الأنماط المصلیة الأخرى دون المستدمیة النزلیة من<br />النوع ب، أو ضد التهاب السحا 􀇽ا الذي تسببه أنواع أخ رى من المیكرو 􀈃ا ت.<br /><strong>الأطفال</strong><br />غیر قابل للتطبیق .<br /><strong>أدو 􀈂ة أخرى و 􀈁ِنتاكسیم، مسحوق ومُ ع لق لتحضیر مُعلّ ق للحقن في محقنة مسبقة التعبئة</strong><br />􀇽مكن إعطاء هذا اللقاح 􀇼الت ا زمن مع لقاح M-M-RVAXPRO أو لقاح HBVAXPRO ، ولكن في<br />مو ضعین منفصلین، أي في موضعین مختلفین من الجسم، مثل الذ ا رع الأخرى أو الساق الأخرى .</p><p>و في حالة الرغبة في تطعیم طفلك ببِنتاكسیم في وقت واحد مع لقاحات أخرى غیر تلك المذ 􀘗ورة أعلاه، یرجى<br />م ا رجعة طبیبك أو الصیدلي للحصول على مز􀈄د من المعلومات.<br />أخبر طبیبك أو الصیدلي إذا 􀘗ان طفلك یتناول، أو تناول مؤخ ا ر أو قد یتناول أي أدو 􀈄ة أخرى .<br /><strong>بِنتاكسیم، مسحوق ومُ ع لق لتحضیر مُعلّق للحقن في م حقنة مسبقة التعبئة مع الطعام والش ا رب</strong><br />غیر قابل للتطبیق .<br /><strong>الحمل والرضاع ة</strong><br />غیر قابل للتطبیق .<br /><strong>القیادة واستخدام الآلات</strong><br />غیر قابل للتطبیق .<br /><strong>بِنتاكسیم، مسحوق ومُ ع لق لتحضیر مُعلّق للحقن في م حقنة مسبقة التعبئة 􀇻حتوي على</strong><br />غیر قابل للتطبیق .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سیتم إعطاء بِنتاكسیم لطفلك من قبل أحد المختصین 􀇼الرعا 􀇽ة الصحی ة<br /><u><strong>الجرعة</strong></u><br />تتكون من حقنتین بینهما فاصل زمني مدته شها رن، تُعطى الحقنة الأولى في عمر شهر􀈄ن، والثانیة في عمر<br />٤ أشهر، تلیها حقنة مُ عززة في سن ١١ شه اً ر.<br /><u><strong>طر 􀈂قة الحقن</strong></u><br />􀇽جب حقن اللقاح في العضل، و 􀈄فضل أن 􀇽كون في الجانب الأمامي الجانبي للفخذ (الثلث الأوسط) عند<br />الرضع، وفي الجزء العلوي من الذ ا رع عند الأطفال.</p><p><strong>إذا استخدمت من بِنتاكسیم؛ مسحوق ومُعلّق لتحضیر مُع لق للحقن في مِحقنة مسبقة التعبئة أكثر مما<br />ینبغي</strong><br />غیر قابل للتطبیق .<br /><strong>إذا نسیت استخدام بِنتاكسیم؛ مسحوق ومُعلّق لتحضیر مُع لق للحقن في مِحقنة مسبقة التعبئة</strong><br />إذا نسیت إعطاء طفلك جرعة مُجدولة من اللقاح، فمن المهم أن تناقش ذلك مع طبیبك الذي سیقرر موعد<br />إعطاء الج رعة الفائتة .<br /><strong>إذا توقفت عن استخدام بِنتاكسیم؛ مسحوق ومُعلّق لتحضیر مُع لق للحقن في مِحقنة مسبقة التعبئة</strong><br />غیر قابل للتطبیق .<br />إذا 􀘗ان لد 􀇽ك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبیبك أو الصیدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع سائر الأدو 􀈄ة، 􀇽مكن أن 􀇽سبب هذا الدواء أع ا رضًا جانبیّة و􀈂ن 􀘗انت لا تحدث لد ى جمیع<br />من یتلقّاه .<br /><strong>ردود الفعل التحسسیة الخطیرة</strong><br />قد تحدث ردود فعل تحسسیة خطیرة 􀇼عد التطعیم، 􀇼شكل عام بینما لا ی ا زل الطفل موجودًا في المكان الذي<br />تلقى اللقاح فیه، على الرغم من أنها نادرة للغا 􀇽ة .<br /><strong>في حالة حدوث أي من الأع ا رض الواردة أدناه 􀇺عد مغادرة المكان الذي تلقى فیه طفلك الحقن، 􀇻جب<br />استشارة الطبیب أو خدمات الطوارىء فو ا رً:</strong><br />&bull; تورم في الوجه (وذمة الوجه)، وتورم مفاجئ في الوجه والرقبة (وذمة وعائیة، وذمة 􀘗و 􀈄نك).<br />&bull; الشعور 􀇼التعب المفاجئ والخطیر مع انخفاض ضغط الدم مما 􀇽سبب الدوخة وفقدان الوعي وتسارع معدل<br />ضر􀈃ات القلب المرتبط 􀇼اضط ا ر 􀇼ات الجهاز التنفسي (رد الفعل التأقي والصدمة).</p><p><strong>الأع ا رض الجانبیة الأخرى</strong><br />إذا تعرّض طفلك لأي من الأع ا ر ض الجانبیة التالیة، أو عند استم ا رر حدوث الأع ا رض الجانبیة أو تفاقمها،<br />یرجى الاتصال 􀇼طبیبك أو الصیدلي.<br /><u>ردود الفعل الشائعة جدًا (قد تؤثر على أكثر من طفل واحد من بین ١٠ أطفال)</u><br />&bull; فقدان الشهیة .<br />&bull; العصبیة والهیجان .<br />&bull; 􀇼كاء غیر طبیعي .<br />&bull; النعاس .<br />&bull; التقیؤ .<br />&bull; احم ا رر في موضع الحقن (حمامي).<br />&bull; الحمى تصل إلى ٣٨ درجة مئو 􀈄ة أو أعلى .<br />&bull; تورم في موضع الحقن (وذمة).<br />&bull; ألم في م وضع الحق ن<br /><u>ردود الفعل الشائعة (قد تؤثر على أقل من واحد من 􀘗ل ١٠ أطفال ولكن أكثر من واحد من 􀘗ل ١٠٠ طفل)</u><br />&bull; إسهال.<br />&bull; تیبّس موقع الحقن (الجساوة).<br />&bull; الأرق واضط ا رب النوم .<br /><u>ردود الفعل غیر الشائعة (قد تؤثر على أقل من واحد من بین 􀘗ل ١٠٠ طفل ولكن أكثر من واحد من 􀘗ل<br />١٠٠٠ طفل)</u></p><p>&bull; احم ا رر وتورم في موضع الحقن (وذمة) 􀇽متد لقطر 􀇽صل إلى ٥ سم أو أكثر .<br />&bull; الحمى التي تصل إلى ٣٩ درجة مئو 􀈄ة أو أعلى .<br />&bull; 􀇼كاء مطوّل بدون توقف 􀇽صعب تهدئته (لأكثر من ٣ ساعات )<br /><u>ردود الفعل النادرة (قد تؤثر على أقل من طفل واحد من بین ١٠٠٠ طفل ولكن أكثر من واحد من بین<br />١٠٠٠٠ طفل)</u><br />&bull; حمى تز􀈄د عن ٤٠ درجة مئو 􀈄ة .<br />&bull; التورم في الساقین والقدمین (وذمة تؤثر على الأط ا رف السفلیة) مع ازرقاق لون الجلد (زرقة) أو احم ا رر،<br />وظهور 􀇼قع حم ا رء عابرة صغیرة (فرفر􀈄ة) تحدث في غضون ساعات من التطعیم، وتختفي دون علاج<br />و 􀈃دون عواقب . قد 􀇽صاحب التورم 􀇼كاء شدید .<br /><u>ردود الفعل ذات التردد غیر المعروف (لا 􀇽مكن تقدیر الترددات لأن ردود الفعل هذه یتم الإبلاغ عنها في<br />حالات نادرة جدًا)</u><br />&bull; تشنجات مع أو بدون حمى.<br />&bull; تدني في الطاقة أو قد یبدو طفلك شاحبًا ومُ تثاقلًا مع عدم القدرة على الاستجا 􀇼ة لفترة من الزمن أو قد یبدو<br />في حالة تشبه الصدمة (ارتخاء أو نو 􀈃ات ارتخاء وانخفاض رد الفعل).<br />&bull; طفح جلدي، احم ا رر (حمامي)، حكة (شرى) .<br />&bull; ردود أفعال 􀘗بیرة في م وضع الحقن (تمتد لقطر أكثر من ٥ سم)، 􀇼ما في ذلك تورم الأط ا رف الموسّع الذي<br />􀇽متد من م وض ع الحقن إلى المفاصل في 􀘗لا جانبي موضع الحقن. تبدأ هذه التفاعلات في غضون ٢٤ -<br />٧٢ ساعة 􀇼ع د التطعیم، وقد تت ا رفق مع الاحم ا رر، والدفء، والإیلام أو الألم في م وضع الحقن، وتتحسن<br />عادة في غضون ٣ - ٥ أ 􀇽ام تلقائیًا دون الحاجة إلى<u> </u>العلاج<u>.</u></p><p>الأع ا ر ض الجانبیة المحتملة (أي التي لم یتم الإبلاغ عنها مباشرة مع بِنتاكسیم، ولكن مع اللقاحات الأخرى<br />التي تحتوي على واحد أو أكثر من المستضدا ت المكونة لبِنتاكسیم) هي 􀘗التالي :<br />&bull; متلازمة غیلان 􀇼ار􀈄ه (حساسیة غیر طبیعیة، شلل) والتهاب العصب العضدي (شلل، ألم منتشر في الذ ا رع<br />والكتف) 􀇼عد إعطاء لقاح 􀇽حتوي على ذوفان الك ا زز.<br /><u><strong>معلومات إضاف یة تتعلق ببعض الفئات</strong></u><br />قد تطول الفت ا رت بین النفَس والآخر لدى الأطفال الذین یولدون قبل الأوان &quot;الخُدّج&quot; (في الأسبوع ٢٨ من<br />الحمل أو قبله)، أكثر من المعتا د لمدة یومین إلى ٣ أ 􀇽ام 􀇼عد التطعیم.<br /><strong><u>الإبلاغ عن الأع ا رض الجانبی ة</u></strong><br />إذا تعرض طفلك لأي أع ا رض جانبیة، فتحدث مع طبیبك أو الصیدلي أو الممر ض(ة). وهذا 􀇽شمل أي<br />أعراض جانبیة محتملة غیر مدرجة في هذه النشرة. 􀇽مكنك أ 􀇽ضًا الإبلاغ عن الأعراض الجانبیة مباشرة عبر<br />نظام الإبلاغ الوطني .<br />􀇽مكنك المساعدة في توفیر المز􀈄د من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض<br />الجانبیة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء 􀇼عیدًا عن أنظار ومتناول الأطفال .<br />لا تستخدم هذا الدواء 􀇼عد تار􀈄خ انتهاء الصلاحیة المذ 􀘗ور على الملصق، والعلبة 􀇼عد 􀘗لمة &quot; EXP &quot;. 􀇽شیر<br />تار􀈄خ انتهاء الصلاحیة إلى الیوم الأخیر من ذلك الشهر.<br />􀇽ُحفظ في الثلاجة ( ٢ درجة مئو 􀈄ة - ٨ درجة مئو 􀈄ة). لا تجم ده.</p><p>لا تستخدم هذا الدواء إذا لاحظت لونًا غیر طبیعي أو وجود جز􀈄ئات غر􀈄بة .<br />لا تتخلص من أي أدو 􀈄ة عن طر􀈄ق میاه الصرف الصحي أو النفا 􀇽ات المنزلیة. اسأل الصیدلي عن 􀘗یفیة<br />التخلص من الأدو 􀈄ة التي لم تعد تستخدمها. ستساعد هذه الإج ا رءات على حما 􀇽ة البیئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مكوّنات بِنتاكسیم؛ مسحوق ومُعلّق لتحضیر مُعلق للحقن في مِحقنة مسبقة التعبئة<br />&bull; المواد الفعّالة:<br />تحتوي 􀘗ل جرعة ( ٠٬٥ مل) من اللقاح 􀇼عد إعادة تشكیله على :<br />ذ 􀇽فان الخُنَّاق( ١ ) &ge; ٣٠ وحدة<br />ذ 􀇽فان الك ا زز( ١) &ge; ٤۰ وحدة<br />مُستضدات البوردیتیلا الشاهوقیة &quot;السعال الد 􀇽كي&quot;<br />ذ 􀇽فان السعال الد 􀇽ك ي( ١) ٢٥ میكروج ا ر م<br />هیم أجلوتینین الخیطي( ١ ) ٢٥ میكروج ا ر م<br />فیروس شلل الأطفال (المُعطّل)<br />النوع الأول ( D ٤٠ (Mahoney وحدات مُستض د( ٢)( ٣)( ٤)<br />النوع الثاني ( D ٨ (MEF-1 وحدات مُستض د ٢)( ٣)( ٤)<br />النوع الثالث ( D ٣٢ (Saukett وحدات مُستض د ٢)( ٣)( ٤)<br />المُستدمیة النزلیة نوع ب عدید السكّر􀈄 د ١٠ میكروج ا ر م<br />مقترن ببروتین الك ا زز ١٨ - ٣٠ میكروج ا ر م</p><p>مُمتزّ على هیدرو 􀘗سید الألمنیوم المُمیّ ه ٠٬٣ مجم + Al3<br />٢وحدة مستضد دولیة<br />٣ كمیة مُستضد 􀇽ة مُكافئة في اللقاح تُحدد 􀇼طر􀈄قة 􀘗یمیائیة مناعیة مناسبة<br />٤ مُنتجة على خلا 􀇽ا فیر و<br />&bull; المكونات الأخرى:<br />o وسط هانكس بدون الفینول الأحمر<br />o حمض الخل الجلیدي و / أو هیدرو 􀘗سید الصودیوم (لتعدیل درجة الحموضة)<br />o فورمالدهای د<br />o فینو 􀘗سي إیثانو ل<br />o الإیثانول<br />o الماء المُخصص للحقن .<br />وسط هانكس هو خلیط معقد من الأحماض الأمینیة ( 􀇼ما في ذلك فینیل ألانین) والأملاح المعدنیة<br />والفیتامینات والمكونات الأخرى (مثل الجلو 􀘗وز) المخفف في الماء المخصص للحقن.<br />المسحوق:<br />o السكارو ز<br />o ترومیثامو ل<br />o حمض الهیدرو 􀘗لور􀈄ك المر 􀘗ز لتعدیل درجة الحموضة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">بِنتاكسیم هو مسحوق ومع لق للحقن ( ٠.٥ مل في محقنة مسبقة التعبئة مع أو بدون إبرة. تحتوي العلبة على<br />١ أو ١٠ أو ٢٠ محقنة)<br />المسحوق أبیض والمذیب عكر ولونه مائل للأبی ض.<br />قد لا یتم تسو 􀈄ق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسو 􀈂 ق</strong><br />سانوفي 􀇼استو ر<br />١٤ وادي إسباس هنر ي<br />٦٩٠٠٧ لیون &ndash; فرنسا<br /><strong>التعبئة الثانو 􀈂ة :</strong><br />الشر 􀘗ة العر􀈃یة للمنتجات الصیدلانیة ( ARABIO (<br />القطعة رقم ٦، منطقة مكة الصناعیة، حي العمرة ،<br />مكة المكرمة، المملكة العر􀈃یة السعود 􀇽ة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            یولیو ٢٠٢٠
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PENTAXIM, powder and suspension for suspension for injection in prefilled syringe Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and
Haemophilus type b conjugate vaccine, adsorbed
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution one dose (0.5 ml) contains:
Diphtheria toxoid (1) .................................................................................................................................................................................... ≥ 30 IU (2)
Tetanus toxoid (1) ......................................................................................................................................................................................... ≥ 40 IU (3)
Bordetella pertussis antigens:
Pertussis toxoid (1) ......................................................................................................................................................................... 25 micrograms
Filamentous haemagglutinin (1) ........................................................................................................................................... 25 micrograms
Poliomyelitis virus (inactivated)
- type 1 (Mahoney strain) ...................................................................................................... 40 DU (4) (5) (6)
- type 2 (MEF-1 strain) ............................................................................................................ 8 DU (4) (5) (6)
- type 3 (Saukett strain) ......................................................................................................... 32 DU (4) (5) (6)
Polysaccharide of Haemophilus influenzae type b ............................................................. 10 micrograms
conjugated to the tetanus protein ................................................................................. 18-30 micrograms
(1) adsorbed on aluminium hydroxide, hydrated ........................................................................................ 0.3 mg Al3+
(2) As mean value
(3) As lower confidence limit (p=0.95)
(4) DU: D antigen unit.
(5) or equivalent antigenic quantity determined by a suitable immunochemical method.
(6) produced on VERO cells.
PENTAXIM may contain traces of glutaraldehyde, neomycin, streptomycin and polymyxin B (see section 4.3).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and suspension for suspension for injection.
PENTAXIM is made up of a syringe prefilled with a cloudy, whitish, sterile suspension and a vial of white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This vaccine is indicated in the joint prevention of diphtheria, tetanus, pertussis, poliomyelitis and<br />invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia,<br />cellulitis, arthritis, epiglottitis, etc.),<br />&bull; for primary vaccination in infants from the age of 2 months,<br />&bull; for booster vaccination, one year after primary vaccination during the second year of life.</p><p>This vaccine does not protect against infections caused by the other types of Haemophilus influenzae<br />or against meningitis due to other micro-organisms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PENTAXIM must be administered according to the official recommendations in effect.<br /><u><strong>Posology</strong></u><br /><em>Paediatric population</em><br />Primary vaccination: 3 injections given at an interval of one month, i.e. according to the official<br />schedule, at the age of 2, 3, 4 months.<br />Booster vaccination: 1 injection one year after primary vaccination, i.e. usually between 16 and 18 months.<br /><u><strong>Method of administration</strong></u><br />Administer via the intramuscular route (IM).<br />Administration should preferably be performed in the anterolateral side of the thigh (middle third) in infants and in the deltoid area in children.<br />For instructions on reconstitution of the medicine before administration, see section 6.6. Once reconstituted, the suspension is cloudy and whitish.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity:
o to any of the active substances of PENTAXIM,
o to any of the excipients listed in section 6.1,
o to glutaraldehyde, neomycin, streptomycin, or polymyxin B (used during the manufacturing process and which may be present as traces),
o to a pertussis vaccine (acellular or “whole cell”).
• Life-threatening reaction after previous injection of the vaccine or a vaccine containing the same substances.
• Vaccination must be postponed in case of fever or acute disease.
• Evolving encephalopathy.
• Encephalopathy within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (“whole cell” or acellular pertussis vaccines).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The immunogenicity of PENTAXIM may be reduced by immunosuppressive treatment or immunodeficiency. It is then recommended to wait until the end of the treatment or disease before vaccinating. Nevertheless, vaccination of subjects with chronic immunodeficiency such as HIV infection is recommended even if the immune response may be limited.<br />If Guillain-Barr&eacute; syndrome or brachial neuritis has occurred in subjects following receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks of vaccination. Vaccination is usually justified for infants whose primary immunization schedules are incomplete (i.e. fewer than three doses administered).<br />Do not inject via the intravascular route: make sure the needle does not penetrate a blood vessel. Do not inject via the intradermal route.<br />As with all injectable vaccines, PENTAXIM must be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.<br />Vaccination must be preceded by medical history screening (especially with regard to vaccination</p><p>history and any occurrence of undesirable events) and a clinical examination.<br />If any of the following events are known to have occurred in temporal relation to receipt of vaccine, the decision to give further doses of pertussis-containing vaccine should be carefully considered:<br />&bull; Fever &ge; 40&deg;C within 48 hours not due to another identifiable cause.<br />&bull; Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.<br />&bull; Persistent, inconsolable crying lasting &ge; 3 hours, occurring within 48 hours of vaccination.<br />&bull; Convulsions with or without fever, occurring within 3 days of vaccination.<br />A history of febrile convulsions not related to a previous vaccine injection is not a contraindication to vaccination.<br />In this respect, it is particularly important to monitor the temperature in the 48 hours following vaccination and to give antipyretic treatment regularly for 48 hours.<br />A history of afebrile convulsions not related to a previous vaccine injection should be assessed by a specialist before deciding to vaccinate.<br />In the event of oedematous reactions occurring in the lower limbs after injection of a Haemophilus influenzae type b-containing vaccine, the two vaccines, diphtheria-tetanus-pertussis-poliomyelitis vaccine and the Haemophilus influenzae type b conjugate vaccine should be administered in two separate injection sites and on two different days.<br />As with all injectable vaccines, appropriate medical treatment must be readily available and close supervision provided should a rare anaphylactic reaction occur following administration of the vaccine.<br />PENTAXIM does not protect against invasive diseases caused by serotypes other than Haemophilus influenzae type b, nor against meningitis from other origins.<br />The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunisation series to very premature infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.<br />Interference with laboratory tests: see section 4.5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This vaccine can be administered simultaneously with the M-M-RVAXPRO vaccine or with the HBVAXPRO vaccine, but in two separate sites.<br /><em><strong>Interference with laboratory tests</strong></em><br />Since the Hib capsular polysaccharide antigen is excreted in the urine, a positive urine test can be observed within 1 to 2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />PENTAXIM is intended for paediatric use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />PENTAXIM is intended for paediatric use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse events are ranked under headings of frequency using the following convention: Very common: &ge; 10%<br />Common: &ge; 1% and &lt; 10%<br />Uncommon: &ge; 0.1% and &lt; 1%<br />Rare: &ge; 0.01% and &lt; 0.1% Very rare: &lt; 0.01%<br />Not known: cannot be estimated from the available data.<br />Based on spontaneous reports, certain undesirable events were very rarely reported following the use of PENTAXIM. Because events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. This is why these undesirable events are ranked under the &laquo; Not known &raquo; frequency.<br />In clinical studies in children who received PENTAXIM as a primary series, the most frequently reported reactions are local injection-site reactions, abnormal crying, irritability and fever.<br />These signs and symptoms usually occur within 48 hours following the vaccination and may continue for 48-72 hours. They resolve spontaneously without specific treatment.<br />The frequency of injection-site reactions tends to increase at booster vaccination compared with the frequency observed for primary series.</p><p><strong>Immune system disorders</strong><br />Reactions with a Not Known frequency<br />&bull; Immediate hypersensitivity reactions such as face oedema, angioedema, Quincke&rsquo;s oedema, anaphylactic reactions and shocks.<br /><strong>Metabolism and nutrition disorders</strong><br />Very common reactions<br />&bull; Loss of appetite.<br /><strong>Psychiatric disorders</strong><br />Very common reactions<br />&bull; Nervousness, irritability.<br />&bull; Abnormal crying.</p><p>Common reactions<br />&bull; Insomnia, sleep disturbances.<br />Uncommon reactions<br />&bull; Prolonged inconsolable crying.<br /><strong>Nervous system disorders</strong><br />Very common reactions<br />&bull; Somnolence.<br />Reactions with a Not Known frequency<br />&bull; Convulsions with or without fever.<br />&bull; Hypotonic-hyporesponsive episodes.<br /><strong>Gastro-intestinal disorders</strong><br />Very common reactions<br />&bull; Vomiting.<br />Common reactions<br />&bull; Diarrhoea.<br /><strong>Skin and subcutaneous tissue disorders</strong><br />Reactions with a Not Known frequency<br />&bull; Rash, erythema, urticaria.<br /><strong>General disorders and administration site conditions</strong><br />Very common reactions<br />&bull; Injection-site erythema.<br />&bull; Fever &ge;38&deg;C.<br />&bull; Injection-site oedema.<br />&bull; Injection-site pain.<br />Common reactions<br />&bull; Injection-site induration.<br />Uncommon reactions<br />&bull; Fever &ge;39&deg;C.<br />&bull; Injection-site redness and oedema &ge;5 cm.<br />Rare reactions<br />&bull; Fever &gt;40&deg;C.<br />OEdematous reactions on one or on both lower limbs may occur after vaccination with a Haemophilus influenzae type b conjugate-containing vaccine. These reactions generally occur after primary series, within hours of the vaccination, and resolve without sequelae within 24 hours. These reactions may be accompanied with cyanosis, erythema, transient purpura and severe crying.<br />Reactions with a Not Known frequency<br />&bull; Large injection-site reactions (&gt; 50 mm), including extensive limb swelling that may spread from the injection site to one or both adjacent joints. These reactions start within 24-72 hours after vaccination and may be associated with symptoms such as erythema, warmth, tenderness or pain at the injection site. They resolve spontaneously within 3-5 days. The risk appears to be dependent on the number of prior doses of acellular pertussis-containing vaccines, with a greater risk following the 4th and 5th doses.<br /><strong>Potential undesirable effects</strong> (i.e. that have not been reported directly with PENTAXIM, but with other vaccines containing one or more of the antigenic constituents of PENTAXIM):<br />&bull; Guillain-Barr&eacute; Syndrome and brachial neuritis after administration of a tetanus toxoid-containing vaccine.</p><p><strong>Complementary information concerning specific populations</strong><br />Apnoea in very premature infants (born &le; 28 weeks of gestation) (see section 4.4).<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system</p><p>To reports any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not documented.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: Bacterial and viral vaccines, combined, ATC code: J07CA06.</strong><br />Diphtheria and tetanus toxins are detoxified using formaldehyde and then purified.<br />The poliomyelitis vaccine is obtained from the propagation of poliomyelitis virus types 1, 2 and 3 on Vero cells, purified, then inactivated by formaldehyde.<br />The acellular pertussis components (PT and FHA) are extracted from Bordetella pertussis cultures, then purified. The pertussis toxin (PT) is detoxified by glutaraldehyde and corresponds to the pertussis toxoid (PTxd). The FHA is native. It has been shown that PTxd and FHA are two components of major importance for protection against pertussis.<br />The PRP capsular polysaccharide (polyribosyl ribitol phosphate: PRP) is extracted from the culture of Haemophilus influenzae type b and conjugated to the tetanus protein (T) to give the PRP-T conjugate vaccine.<br />The PRP capsular polysaccharide (polyribosyl ribitol phosphate: PRP) induces an anti-PRP serological response in humans. However, as for all polysaccharide antigens, the immune response is thymo-independent, characterised by a low immunogenicity in infants and by the absence of a booster effect before the age of 15 months. The covalent bond of the Haemophilus influenzae type b capsular polysaccharide to a carrier protein, the tetanus protein, enables the conjugate vaccine to behave like a thymo-dependent antigen inducing a specific anti-PRP serological response in infants and to obtain a booster effect.<br />Immune response after primary vaccination:<br />Immunogenicity studies in infants have shown that, one month after the third dose of the primary vaccination, all (100%) developed a seroprotective antibody level (&gt; 0.01 IU/ml) to both diphtheria and tetanus antigens.<br />As for pertussis, one month after the third dose of the primary vaccination, 93% of infants achieved a four-fold rise in PT antibodies and more than 88% in FHA antibodies.<br />At least 99% of children had seroprotective antibody titres to poliomyelitis virus types 1, 2 and 3 (&ge; 5</p><p>as expressed by reciprocal of dilution in seroneutralisation).<br />At least 97.2% of infants achieved anti PRP titres above 0.15 &mu;g/ml one month after the third dose of the primary vaccination.<br />Immune response after the booster:<br />After the first booster dose (16-18 months), all the toddlers developed protective antibodies against diphtheria (&gt; 0.1 IU/ml), tetanus (&gt; 0.1 IU/ml), poliomyelitis viruses (&ge; 5 as expressed by reciprocal of dilution in seroneutralisation).<br />The seroconversion rate in pertussis antibodies (titres higher than four-fold the pre-vaccinal titers) is at least 98% for PT (EIA) and 99% for FHA (EIA).<br />An antibody titre anti-PRP &ge; 1.0 &mu;g/ml was reached in all toddlers.<br />A follow-up study of pertussis immunogenicity in children at 5-6 years of age has shown that the antibody titres anti-PT and anti-FHA of children vaccinated for primary course and booster with acellular combined vaccines were at least equivalent to those observed at the same age in children vaccinated with whole pertussis combined vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional acute toxicity, repeat dose toxicity and local tolerance studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concerning the adsorbent, see section 2. Suspension for injection:<br />&bull; Hanks&#39; medium (without phenol red) 0.05 ml<br />&bull; Acetic acid glacial and/or sodium hydroxide (for pH adjustment)<br />&bull; Formaldehyde 10 &mu;g<br />&bull; Phenoxyethanol 2.5 &mu;l<br />&bull; Ethanol 2.5 &mu;l<br />&bull; Water for injections. qs 0.5 ml<br />Hanks medium is a complex mixture of amino acids (including phenylalanine), mineral salts, vitamins and other components (such as glucose) diluted in water for injections.<br />Powder:<br />&bull; Saccharose 42.5 mg<br />&bull; Tromethamol 0.6 mg<br />&bull; Concentrated hydrochloric acid for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
The vaccine must be administered immediately after reconstitution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Do not freeze.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Powder in vial (type I glass) equipped with a stopper (chlorobutyl) + 0.5 ml of suspension in prefilled syringe (type I glass) equipped with a plunger-stopper (bromobutyl or chlorobutyl or bromochlorobutyl). Box of 1<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For syringes without attached needles, the needle must be fitted firmly to the syringe, rotating it by a one-quarter turn.<br />Reconstitute the solution by injecting the suspension of the combined diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine into the vial with the powder of the Haemophilus type b conjugate vaccine. Shake until complete dissolution of the powder. After reconstitution, the whitish-turbid appearance of the suspension is normal.<br />The vaccine must be used immediately after reconstitution.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SANOFI PASTEUR
14 ESPACE HENRY VALLÉE
69007 LYON FRANCE
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15th July 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>